Over a billion people worldwide live in regions where 20%-50% of marriages are consanguineous - that is where the partners are descended from the same ancestor.

FDA is continuing to work with the manufacturers of these drug products to develop and implement means to mitigate the risks of fetal exposure. See the FDA Healthcare Professional Information Sheet containing considerations and recommendations for clinicians prior to prescribing MMF or MPA to women of childbearing potential.

Henry Reid, the former director of UCLA’s willed body program, allegedly sold donated body parts to businessman Ernest Nelson, who then resold them to medical, pharmaceutical and hospital research companies.

“As a result, Ernest Nelson was able to supply over 20 of his clients with hundreds of body parts and received over $1 million for the supplied body parts,” according to the indictment.

“We believe the events that led to our voluntarily closing the Lufkin Dialysis center are the result of a criminal act by an individual who has been terminated and is no longer working at the center,” said DaVita spokesman Michael Chee.

In February, 2008, an independent monitoring committee stopped the Phase III trial after interim results were positive and allowed researchers to offer everolimus to the patients receiving placebo.

The donor, a 49-year-old homeless man who suffered irreversible brain damage after cardiac arrest, carried a germ called lymphocytic choriomeningitis virus, or LCMV, the same infection that killed three transplant patients from Massachusetts and Rhode Island in 2005. The virus, most often transmitted by rodents, is usually unnoticed by healthy people who suffer no more than flulike symptoms.

[UPDATE 05/15/2008] Medtronic Inc., initiated a voluntary recall of selected products featuring the Carmeda BioActive surface. The recalled products are used during cardiopulmonary bypass heart surgeries. Limited lots of Carmeda-coated products were manufactured with heparin found to have been contaminated with oversulfated chondroitin sulfate (OSCS). It is unclear if exposure to Carmeda-coated medical devices, made with small amount of heparin, could cause adverse events similar to those observed with injectable heparin formulations. Patient risk associated with the presence of OSCS in heparin-coated medical devices is not known at this time.